The development and internal consistency of the satisfaction with Antipsychotic Medication Scale.

Psychol Med

Health Services Research Department, Institute of Psychiatry, De Crespigny Park, London, UK.

Published: July 2005

AI Article Synopsis

  • The Satisfaction with Antipsychotic Medication (SWAM) scale was developed to measure patient satisfaction, addressing a gap in existing measures.
  • A 33-item Likert scale was created by experts and validated through a study involving 315 individuals with schizophrenia, showing strong reliability and internal consistency.
  • The SWAM scale is deemed a reliable tool for evaluating satisfaction with antipsychotic medication and can be implemented in mental health services for routine assessments.

Article Abstract

Background: Satisfaction with antipsychotic medication is an important outcome variable. To date, there is a lack of a well-established measure to quantify patient satisfaction with psychiatric medication. This paper describes the development, dimensionality, reliability and validity of the Satisfaction with Antipsychotic Medication (SWAM) scale.

Method: Clinical and academic experts devised a 33-item Likert scale satisfaction questionnaire. Following a pilot study in a sample of 69 people with schizophrenia, 315 people with schizophrenia on the caseload of local mental health services in three London boroughs completed the questionnaire. The dimensionality, internal consistency and validity of the devised instrument were assessed.

Results: Reliability of the SWAM scale was good for subscales and total scores. The alpha coefficient for the two subscales: treatment acceptability and medication insight were 0.92 and 0.84 respectively. The a coefficient for the SWAM scale total score was 0.91 and ranged from 0.92 to 0.90.

Conclusion: Testing of the psychometric properties of the SWAM scale demonstrate that it is a reliable instrument for measuring patient satisfaction with antipsychotic medication. The measure could be used in routine clinical practice in mental health services to assess patient satisfaction with psychiatric medication.

Download full-text PDF

Source
http://dx.doi.org/10.1017/s0033291705004526DOI Listing

Publication Analysis

Top Keywords

satisfaction antipsychotic
16
antipsychotic medication
16
patient satisfaction
12
swam scale
12
internal consistency
8
satisfaction psychiatric
8
psychiatric medication
8
people schizophrenia
8
mental health
8
health services
8

Similar Publications

The development of paliperidone nanocrystals for the treatment of schizophrenia.

Prog Biomed Eng (Bristol)

November 2024

State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, People's Republic of China.

Schizophrenia is a complex and chronic psychiatric disorder that significantly impacts patients' quality of life. Ranking 12th among 310 diseases and injuries that result in disability, the number of patients suffering from schizophrenia continues to rise, emphasizing the urgent need for developing effective treatments. Despite the availability of effective antipsychotic drugs, over 80% of patients taking oral antipsychotics experience relapses, primarily caused by non-adherence as the high dosing frequency is required.

View Article and Find Full Text PDF

Quality of life is a multidimensional concept that includes both positive and negative aspects of well-being and life, as well as social, psychological and physical health. It is related to health and refers to the optimal level of mental, physical and social functioning.The aim of the research was to examine the effects of vortioxetine on the quality of life in patients with schizophrenia.

View Article and Find Full Text PDF

Background: Although second-generation antipsychotics (SGAs) have proven to be effective therapeutic options for patients with schizophrenia, there is a notable lack of evidence on patients' subjective perspectives regarding their well-being, quality of life, and satisfaction with these medications. This study aimed to evaluate the treatment satisfaction and effectiveness of lurasidone on quality of life and functioning in adult patients with schizophrenia in real-world Italian clinical practice.

Methods: This was a multicentre, national, non-interventional, single-arm, 3-month prospective study.

View Article and Find Full Text PDF

Background: Schizophrenia treatment with antipsychotics often results in side effects that impact adherence and quality of life. Managing these effects remains challenging, as it requires balancing efficacy and tolerability. The Schizophrenia Technological Evaluation of Patient Side Effects (STEP-SE) app aims to aid side effects monitoring and management through shared decision-making (SDM).

View Article and Find Full Text PDF

Background: Sexual dysfunction (SD) is a significant issue among psychiatric patients on psychotropic medications. This study aims to compare SD in patients using antipsychotics and antidepressants.

Objective: To evaluate the prevalence of SD and its effect on the quality of life among psychiatric patients on medications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!